‘Organoid-on-a-chip’ has already been used to evaluate Covid vaccine efficacy in China, but a lack of regulation means the uptake of the niche technology is lagging behind the West
A new technology combining minute, lab-grown slivers of the human body with microchips is piquing the interest of pharmaceutical companies and health care investors in China, as it offers a new and potentially lucrative type of personalized care that could disrupt the traditional drug industry…….
This article has a total of 1507 words. Continue reading after subscribing
https://en.caixin.com/2023-07-28/102089107.html